154 related articles for article (PubMed ID: 37694811)
21. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.
Sheffield BS; Hwang HC; Lee AF; Thompson K; Rodriguez S; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2015 Jul; 39(7):977-82. PubMed ID: 25634745
[TBL] [Abstract][Full Text] [Related]
22. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL; Dacic S; Galateau-Salle F; Attanoos RL; Butnor KJ; Churg A; Husain AN; Kadota K; Khoor A; Nicholson AG; Roggli V; Schmitt F; Tsao MS; Travis WD
J Thorac Oncol; 2022 May; 17(5):608-622. PubMed ID: 35026477
[TBL] [Abstract][Full Text] [Related]
23. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
Cozzi I; Oprescu FA; Rullo E; Ascoli V
Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
[TBL] [Abstract][Full Text] [Related]
24. Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas.
Amacher V; Bode PK; Moch H; Lenggenhager D; Vrugt B
Acta Cytol; 2023; 67(4):444-450. PubMed ID: 36889303
[TBL] [Abstract][Full Text] [Related]
25. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
26. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
27. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
Hung YP; Chirieac LR
Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
[TBL] [Abstract][Full Text] [Related]
28. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
[TBL] [Abstract][Full Text] [Related]
29. Malignant mesothelioma in situ: diagnostic and clinical considerations.
Pulford E; Henderson DW; Klebe S
Pathology; 2020 Oct; 52(6):635-642. PubMed ID: 32829890
[TBL] [Abstract][Full Text] [Related]
30. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
31. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
32. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.
Nabeshima K; Hamasaki M; Kinoshita Y; Matsumoto S; Sa-Ngiamwibool P
Pathol Int; 2022 Aug; 72(8):389-401. PubMed ID: 35596704
[TBL] [Abstract][Full Text] [Related]
33. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
34. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
[TBL] [Abstract][Full Text] [Related]
35. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
36. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
38. Malignant mesothelioma in situ.
Churg A; Hwang H; Tan L; Qing G; Taher A; Tong A; Bilawich AM; Dacic S
Histopathology; 2018 May; 72(6):1033-1038. PubMed ID: 29350783
[TBL] [Abstract][Full Text] [Related]
39. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
Terra S; Roden AC; Yi ES; Aubry MC; Boland JM
Am J Clin Pathol; 2022 Jan; 157(1):33-39. PubMed ID: 34463336
[TBL] [Abstract][Full Text] [Related]
40. Update on Diagnosing and Reporting Malignant Pleural Mesothelioma.
Savic I; Myers J
Acta Med Acad; 2021 Apr; 50(1):197-208. PubMed ID: 34075773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]